Search

James E Zadina

from Metairie, LA
Age ~74

James Zadina Phones & Addresses

  • 3813 Courtland Dr, Metairie, LA 70002 (504) 887-5444
  • 19201 Vista Ln, Indian Shores, FL 33785 (727) 729-5319
  • 19717 Gulf Blvd, Indian Shores, FL 33785 (727) 729-5319
  • 19201 Vista Ln #A4, Indian Rocks Beach, FL 33785 (727) 729-5319
  • New Orleans, LA

Publications

Us Patents

Mu Opioid Receptor Agonist Analogs Of The Endomorphins

View page
US Patent:
20120322740, Dec 20, 2012
Filed:
May 22, 2012
Appl. No.:
13/477423
Inventors:
James E. ZADINA - Metairie LA, US
Laszlo HACKLER - Metairie LA, US
Assignee:
UNITED STATES DEPARTMENT OF VETERANS AFFAIRS - Washington DC
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND - New Orleans LA
International Classification:
C07K 4/00
A61K 38/03
A61P 1/00
G01N 33/566
A61K 38/12
A61P 25/30
C12N 5/071
C07K 7/64
A61P 25/04
US Classification:
514 184, 530321, 514 211, 514 177, 435375, 435 721
Abstract:
The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

Mu-Opiate Receptor Peptides

View page
US Patent:
58859586, Mar 23, 1999
Filed:
Mar 25, 1997
Appl. No.:
8/824109
Inventors:
James E. Zadina - Metairie LA
Abba J. Kastin - Metairie LA
Laszlo Hackler - Metairie LA
Assignee:
Administrators of the Tulane Educational Fund - New Orleans LA
International Classification:
A61K 3812
C07K 512
US Classification:
514 9
Abstract:
This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing a pharmaceutically effective amount of the peptides.

Mu-Opiate Receptor Peptides

View page
US Patent:
63035782, Oct 16, 2001
Filed:
Feb 18, 1999
Appl. No.:
9/252338
Inventors:
James E. Zadina - Metairie LA
Abba J. Kastin - Metairie LA
Laszlo Hackler - Metairie LA
Assignee:
Administrators of the Tulane Educational Fund - New Orleans LA
International Classification:
A61K 3807
C07K 510
US Classification:
514 18
Abstract:
This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing a pharmaceutically effective amount of the peptides.

Mu Opioid Receptor Agonist Analogs Of The Endomorphins

View page
US Patent:
20150315238, Nov 5, 2015
Filed:
May 2, 2014
Appl. No.:
14/268057
Inventors:
James Zadina - Metairie LA, US
Assignee:
UNITED STATES DEPARTMENT OF VETERANS AFFAIRS - Washington DC
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND - New Orleans LA
International Classification:
C07K 7/06
A61K 45/06
G01N 33/94
A61K 38/12
Abstract:
The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.
James E Zadina from Metairie, LA, age ~74 Get Report